食管胃结合部腺癌围手术期治疗研究进展

Research progress of perioperative treatment for esophagogastric junction adenocarcinoma

食管胃结合部腺癌在我国的发病率仍居高不下。近年来,以手术治疗为主,联合化疗、放疗、免疫治疗、靶向治疗等综合治疗模式逐步改善了患者的预后,但围手术期治疗模式还存在不少争议。本文总结了食管胃结合部腺癌围手术期治疗相关研究进展,从术前新辅助治疗、术后辅助治疗、围手术期放疗及免疫治疗等方面进行综述,以明晰目前研究方向。

The incidence of esophagogastric junction adenocarcinoma is still high in China.In recent years,surgical treatment combined with chemotherapy,radiotherapy,immunotherapy,and targeted therapy has gradually improved the prognosis of patients with gastric cancer,but there are still many controversies in the perioperative treatment.This study summarized the research progress related to perioperative treatment for esophagogastric junction adenocarcinoma,including preoperative neoadjuvant therapy,postoperative adjuvant therapy,perioperative radiotherapy,and immunotherapy,so as to clarify the current research direction.